Global Ion Channel Modulators Industry

News provided by

Aug 01, 2013, 07:45 ET

NEW YORK, Aug. 1, 2013 PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Ion Channel Modulators Industry
http://www.reportlinker.com/p01171462/Global-Ion-Channel-Modulators-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Discovery_and_Development

This report analyzes the worldwide markets for Ion Channel Modulators in US$ Million.

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets.

The report profiles 48 companies including many key and niche players such as AstraZeneca, Aurora Biomed, Inc., CalciMedica, Inc., Cellectricon AB, Convergence Pharmaceuticals Limited, Cytocentrics AG, Evotec AG, flyion GmbH, GlaxoSmithKline Plc, Neusentis, Inc., Nanion Technologies GmbH, NeuroSearch A/S, Novartis AG, Parion Sciences, Inc., Pfizer, Inc., Sanofi, Targacept, Inc., Xention Limited, and Zalicus, Inc. Microsoft Corporation, QNX Software Systems Ltd., Renesas Electronics Corporation, VIA Technologies, Inc., and Zilog, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-2
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW II-1
A Prelude II-1
Market Overview II-1
Current Ion Channel Modulating Drugs in the Market II-2
Select Ion Channel Drugs in the Global Market By Disease
Indication II-2
Ion Channel Modulators under Development- A Few Key Facts II-2
Select Ion Channel Modulators under Development by Disease
Indication II-3
Current & Future Analysis II-3
Growth Factors-A Glance II-3
Trends II-3
Technological Advancements in Ion Channel Screening Driving
Drug Development II-3
Increased Interest Witnessed in Outsourcing of Ion Channel
Services II-4
Expanding Areas of Application II-4
Ion Channel Modulators Find Extensive Usage for Treating
Neglected Tropical Diseases II-4
Ion Channel Modulation in Pain Management II-5
Ion Channel Modulation in Oncology II-5
Limitations and Challenges II-5
Ion Channels - Difficult Drug Targets II-5
The threat posed by the influx of generic drugs II-6
Competitive Scenario II-6

2. PRODUCT OVERVIEW II-7
Ion Channel Modulators: An Introduction II-7
Biological Significance of Ion Channels II-7
Ion Channel Modulators as an Option for Treating Diseases II-7
Types of Ion Channels II-8
Voltage-Gated Ion Channels II-8
Extracellular Ligand-gated Ion Channels II-9
Intracellular Ligand-gated Ion Channels II-11

3. PRODUCT LAUNCHES/INTRODUCTIONS II-13
Vertex Pharmaceuticals Receives USFDA Approval for KALYDECO™ II-13
Glenmark Pharmaceuticals Discovers Novel Chemical Entity (NCE)
'GRC 17536' Program II-13
BioFocus DPI Rolls Out Novel Biologically- Targeted Libraries II-14

4. RECENT INDUSTRY ACTIVITY II-15
Aurora Biomed Inks Agreement with Specs and Alion Pharmaceuticals II-15
Hydra and Zalicus Enter into Partnership II-15
Hydra Biosciences and Cubist Pharmaceuticals to Commence Phase
1 Clinical Trial for TRPA1 Antagonist CB-625 II-15
UCB Takes Over Key Pharmaceutical Assets of Lectus Therapeutics II-16
Xention Collaborates with Grünenthal II-16
US FDA Lifts Clinical Hold on ICA-105665 of Icagen II-16
Ono Pharmaceutical Collaborates with BioFocus DPI II-17
Zalicus to Advance Development of Drug Candidate II-17
APEPTICO Concludes Phase I Clinical Trial of AP301 II-17
NeuroSearch Restructures Itself to Focus on CNS Drug Development II-18
Evotec Inks License and Collaboration Agreement for EVT401 II-19
Evotec and Ono Pharmaceutical Extend Research Collaboration II-19
Evotec Acquires DeveloGen II-19
Essen Instruments Enters into Alliance with OriGene Technologies II-20
Glenmark Pharmaceuticals Inks License Agreement with Sanofi-
aventis II-20
Evotec and Active Biotech Enter into Collaboration II-20
CombinatoRx Changes Name to Zalicus II-21
Cytocentrics Expands Ion Channel CRO Screening Services II-21
Icagen and Applied Genetic Technologies Ink Sale and Purchase
Agreement II-21
Evotec Collaborates with Almirall for Identification of Ion
Channel Target Modulators II-22
Essen BioScience and Nycomed Sign Joint Discovery Agreement II-22
Axxam and Polyphor Ink Joint Discovery Agreement II-22
ChanTest Takes Over Applied Cell Sciences II-23
CombinatoRx Merges with Neuromed Pharmaceuticals II-23
Axxam Signs Research Collaboration Agreement with Xenome II-24
Xention and Ono Pharmaceutical Ink Drug Discovery Agreement II-24
NeuroSearch Enters Into Collaboration Alliance with Eli Lilly II-24
Synta Pharmaceuticals Enters Into Strategic Alliance with
Roche Holding II-24
AstraZeneca Inks License and Collaboration Agreement with
Targacept II-25
Abbott Inks Definitive Agreement to Take Over Rights of PG110
Fully Humanized Antibody of PanGenetics II-25
Evotec and Alios BioPharma Enter into Collaboration II-26
Cellectricon and BioFocus DPI Enter into Collaboration II-26
Pfizer Inks License and Collaboration Agreement with Icagen II-26
Dompé farmaceutici Renews Research Collaboration with Axxam II-27
Can-Fite BioPharma Completes Licensing Agreement with Leiden
University and NIH for Allosteric Modulators II-27

5. FOCUS ON SELECT GLOBAL PLAYERS II-28
AstraZeneca (UK) II-28
Aurora Biomed, Inc. (Canada) II-28
CalciMedica, Inc. (US) II-28
Cellectricon AB (Sweden) II-29
Convergence Pharmaceuticals Limited (UK) II-29
Cytocentrics AG (Germany) II-30
Evotec AG (Germany) II-30
flyion GmbH (Germany) II-30
GlaxoSmithKline Plc. (UK) II-31
Neusentis, Inc. (US) II-31
Nanion Technologies GmbH (Germany) II-32
NeuroSearch A/S (Denmark) II-32
Novartis AG (Switzerland) II-32
Parion Sciences, Inc. (US) II-33
Pfizer, Inc. (US) II-33
Sanofi (France) II-34
Targacept, Inc. (US) II-34
Xention Limited (UK) II-34
Zalicus, Inc. (US) II-35

6. GLOBAL MARKET PERSPECTIVE II-36
Table 1: World Recent Past, Current and Future Analysis for
Ion Channel Modulators by Geographic Region - US, Canada,
Japan, Europe, Asia-Pacific (excluding Japan), Latin America,
and Rest of World Markets Independently Analyzed with Annual
Sales in US$ Million for Years 2010 through 2018 (includes
corresponding Graph/Chart) II-36

Table 2: World Historic Review for Ion Channel Modulators by
Geographic Region - US, Canada, Japan, Europe, Asia-Pacific
(excluding Japan), Latin America, and Rest of World Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2004 through 2009 (includes corresponding Graph/Chart) II-37

Table 3: World 15-Year Perspective for Ion Channel Modulators
by Geographic Region - Percentage Breakdown of Dollar Sales
for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),
Latin America, and Rest of World Markets for Years 2004, 2012,
and 2018 (includes corresponding Graph/Chart) II-38

III. MARKET

1. THE UNITED STATES III-1
A.Market Analysis III-1
Overview III-1
Strategic Corporate Developments III-1
Key Players III-6
B.Market Analytics III-9
Table 4: The US Recent Past, Current and Future Analysis for
Ion Channel Modulators with Annual Sales in US$ Million for
Years 2010 through 2018 (includes corresponding Graph/Chart) III-9

Table 5: The US Historic Review for Ion Channel Modulators
with Annual Sales in US$ Million for Years 2004 through 2009
(includes corresponding Graph/Chart) III-10

2. CANADA III-11
A.Market Analysis III-11
Strategic Corporate Development III-11
Aurora Biomed, Inc. - A Key Player III-11
B.Market Analytics III-12
Table 6: Canadian Recent Past, Current and Future Analysis
for Ion Channel Modulators with Annual Sales in US$ Million
for Years 2010 through 2018 (includes corresponding
Graph/Chart) III-12

Table 7: Canadian Historic Review for Ion Channel Modulators
with Annual Sales in US$ Million for Years 2004 through 2009
(includes corresponding Graph/Chart) III-13

3. JAPAN III-14
A.Market Analysis III-14
Strategic Corporate Developments III-14
B.Market Analytics III-15
Table 8: Japanese Recent Past, Current and Future Analysis
for Ion Channel Modulators with Annual Sales in US$ Million
for Years 2010 through 2018 (includes corresponding
Graph/Chart) III-15

Table 9: Japanese Historic Review for Ion Channel Modulators
with Annual Sales in US$ Million for Years 2004 through 2009
(includes corresponding Graph/Chart) III-16

4. EUROPE III-17
A.Market Analysis III-17
Overview III-17
B.Market Analytics III-18
Table 10: European Recent Past, Current and Future Analysis
for Ion Channel Modulators by Country/Region - France,
Germany, Italy, UK, Spain, and Rest of Europe Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2010 through 2018 (includes corresponding Graph/Chart) III-18

Table 11: European Historic Review for Ion Channel
Modulators by Country/Region - France, Germany, Italy, UK,
Spain, and Rest of Europe Markets Independently Analyzed
with Annual Sales in US$ Million for Years 2004 through 2009
(includes corresponding Graph/Chart) III-19

Table 12: European 15-Year Perspective for Ion Channel
Modulators by Country/Region - Percentage Breakdown of
Dollar Sales for France, Germany, Italy, UK, Spain, and Rest
of Europe Markets for Years 2004, 2012, and 2018 (includes
corresponding Graph/Chart) III-20

4a. FRANCE III-21
A.Market Analysis III-21
Sanofi - A Key Player III-21
B.Market Analytics III-22
Table 13: French Recent Past, Current and Future Analysis
for Ion Channel Modulators with Annual Sales in US$ Million
for Years 2010 through 2018 (includes corresponding
Graph/Chart) III-22

Table 14: French Historic Review for Ion Channel Modulators
with Annual Sales in US$ Million for Years 2004 through 2009
(includes corresponding Graph/Chart) III-23

4b. GERMANY III-24
A.Market Analysis III-24
Product Launch III-24
Strategic Corporate Developments III-24
Key Players III-26
B.Market Analytics III-28
Table 15: German Recent Past, Current and Future Analysis
for Ion Channel Modulators with Annual Sales in US$ Million
for Years 2010 through 2018 (includes corresponding
Graph/Chart) III-28

Table 16: German Historic Review for Ion Channel Modulators
with Annual Sales in US$ Million for Years 2004 through 2009
(includes corresponding Graph/Chart) III-29

4c. ITALY III-30
A.Market Analysis III-30
Strategic Corporate Developments III-30
B.Market Analytics III-31
Table 17: Italian Recent Past, Current and Future Analysis
for Ion Channel Modulators with Annual Sales in US$ Million
for Years 2010 through 2018 (includes corresponding
Graph/Chart) III-31

Table 18: Italian Historic Review for Ion Channel Modulators
with Annual Sales in US$ Million for Years 2004 through 2009
(includes corresponding Graph/Chart) III-32

4d. THE UNITED KINGDOM III-33
A.Market Analysis III-33
Product Launch III-33
Strategic Corporate Developments III-33
Key Players III-34
B.Market Analytics III-36
Table 19: The UK Recent Past, Current and Future Analysis
for Ion Channel Modulators with Annual Sales in US$ Million
for Years 2010 through 2018 (includes corresponding
Graph/Chart) III-36

Table 20: The UK Historic Review for Ion Channel Modulators
with Annual Sales in US$ Million for Years 2004 through 2009
(includes corresponding Graph/Chart) III-37

4e. SPAIN III-38
A.Market Analysis III-38
Strategic Corporate Development III-38
B.Market Analytics III-39
Table 21: Spanish Recent Past, Current and Future Analysis
for Ion Channel Modulators with Annual Sales in US$ Million
for Years 2010 through 2018 (includes corresponding
Graph/Chart) III-39

Table 22: Spanish Historic Review for Ion Channel Modulators
with Annual Sales in US$ Million for Years 2004 through 2009
(includes corresponding Graph/Chart) III-40

4f. REST OF EUROPE III-41
A.Market Analysis III-41
Strategic Corporate Developments III-41
Key Players III-44
B.Market Analytics III-46
Table 23: Rest of Europe Recent Past, Current and Future
Analysis for Ion Channel Modulators with Annual Sales in US$
Million for Years 2010 through 2018 (includes corresponding
Graph/Chart) III-46

Table 24: Rest of Europe Historic Review for Ion Channel
Modulators with Annual Sales in US$ Million for Years 2004
through 2009 (includes corresponding Graph/Chart) III-47

5. ASIA-PACIFIC III-48
A.Market Analysis III-48
Product Launch III-48
Strategic Corporate Development III-48
B.Market Analytics III-49
Table 25: Asia-Pacific Recent Past, Current and Future
Analysis for Ion Channel Modulators with Annual Sales in US$
Million for Years 2010 through 2018 (includes corresponding
Graph/Chart) III-49

Table 26: Asia-Pacific Historic Review for Ion Channel
Modulators with Annual Sales in US$ Million for Years 2004
through 2009 (includes corresponding Graph/Chart) III-50

6. LATIN AMERICA III-51
Market Analysis III-51
Table 27: Latin American Recent Past, Current and Future
Analysis for Ion Channel Modulators with Annual Sales in US$
Million for Years 2010 through 2018 (includes corresponding
Graph/Chart) III-51

Table 28: Latin American Historic Review for Ion Channel
Modulators with Annual Sales in US$ Million for Years 2004
through 2009 (includes corresponding Graph/Chart) III-52

7. REST OF WORLD III-53
A.Market Analysis III-53
Strategic Corporate Development III-53
B.Market Analytics III-54
Table 29: Rest of World Recent Past, Current and Future
Analysis for Ion Channel Modulators with Annual Sales in US$
Million for Years 2010 through 2018 (includes corresponding
Graph/Chart) III-54

Table 30: Rest of World Historic Review for Ion Channel
Modulators with Annual Sales in US$ Million for Years 2004
through 2009 (includes corresponding Graph/Chart) III-55

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 48 (including Divisions/Subsidiaries - 50)

The United States (19)
Canada (1)
Japan (2)
Europe (26)
- France (2)
- Germany (6)
- The United Kingdom (9)
- Italy (2)
- Rest of Europe (7)
Asia-Pacific (Excluding Japan) (2)